Liraglutide Effect on Beta-cell Function in C-peptide Positive Type 1 Diabetes
Status:
Completed
Trial end date:
2020-09-01
Target enrollment:
Participant gender:
Summary
Recent studies show that many Type 1 diabetes patients have remaining endogenous insulin
production, albeit at low levels. Finding means to increase this production would be of
tremendous interest, since residual C-peptide concentrations >0.1 nmol/l previously have been
shown to markedly lower HbA1c, decrease blood glucose fluctuations and diminish the risk of
ketoacidosis. It also substantially reduces the risks of severe hypoglycemic events and late
complications. Liraglutide may through its incretin effect directly potentiate beta-cell
function, but also holds the potential to be mitogenic for these cells.
The hypothesis of the present trial is that treatment with liraglutide will not only have a
direct effect on beta-cell function, which is more or less immediately observed, but also
progressively improve C-peptide concentrations over time.